Review anchor
Myosin light chain kinase, smooth muscle
SINGLE PROTEIN · Gallus gallus
As of 2026-09-13
Evidence Snapshot
Myosin light chain kinase, smooth muscle
CHEMBL3062
SINGLE PROTEIN
Gallus gallus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Myosin light chain kinase, smooth muscle as ChEMBL target CHEMBL3062, mapped to UniProt P11799. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3062
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P11799
Myosin light chain kinase, smooth muscle
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Myosin light chain kinase, smooth muscle matters
Myosin light chain kinase, smooth muscle is reviewed as Myosin light chain kinase, smooth muscle (UniProt P11799); the current evidence base includes 1 approved drug, 157 compounds, and 23 assays, with lead potency reaching pChEMBL 10.7.
Protein context
Myosin light chain kinase, smooth muscle
Myosin light chain kinase, smooth muscle Sequence length is 1906 aa.
Review this target as Myosin light chain kinase, smooth muscle, mapped to UniProt P11799. Sequence length is 1906 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P11799
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 157 compounds, and 23 assays for this target. The dominant activity type is IC50. CHEMBL281948 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL281948 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 10.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Myosin light chain kinase, smooth muscle matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P11799, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
157
Total Compounds
23
Total Assays
1
Approved Drugs
IC50: 101.0, KI: 3.0, KD: 38.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL281948
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL522892
|
8.7 | Kd | Clinical |
|
|
No preferred name
CHEMBL388978
|
8.0 | IC50 | — |
|
|
No preferred name
CHEMBL572878
|
7.8 | Kd | Clinical |
|
|
No preferred name
CHEMBL535
|
7.6 | Kd | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
SUNITINIB
CHEMBL535
|
2006 |
Source Header